SCHOTT Pharma Q2 Results Affirm FY 24 Outlook; Slower Syringe Growth to Impact FY 25

• SCHOTT Pharma confirms FY 24 outlook based on Q2 results, with H1 24 revenues up 9% year-on-year at constant currencies to EUR 489m and EBITDA margin of 27.4% at constant currencies.
• FY 25 revenue growth projections are impacted by lower demand for syringes from one customer.
• The company continues to focus on innovation and expansion, tapping into key pharma megatrends for growth.
• Despite slower growth in syringe business in FY 25 due to lower demand from one customer, SCHOTT Pharma confirms its mid-term guidance of organic revenue growth above 10% CAGR and an EBITDA margin in the low 30% range, at constant currencies.
• The company expects the lower syringe demand to be a temporary effect and foresees to compensate this effect in the medium term.
• SCHOTT Pharma will publish its full set of financials for Q2 24 on June 27, 2024.

The price of SCHOTT Pharma at the time of the news was 31,96EUR and was down -12,84 % compared with the previous day.
15 minutes after the article was published, the price was 32,40EUR this corresponds to a plus of +1,38 % since publication.
At this time, the index SDAX was at 15.052,67PKT (+1,21 %).

SCHOTT Pharma

-1,44 %

-0,85 %

-23,96 %

-21,30 %

+9,89 %

ISIN:DE000A3ENQ51WKN:A3ENQ5

• Intraday
• 5 Tage
• 1 Monat
• 3M
• Max